RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP)
RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis
Rarecyte® will presenting a 20 minute talk on the Orion platform as well as a 1 hour technology showcase event during 2021 Molecular Med Tri-Con in Feb 16-18, 2021.
“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”
– Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company